W

ill the Addyi female sexual dysfunction pill ever generate any excitement?

Two years after betting $1 billion on the drug, Valeant Pharmaceuticals (VRX) has agreed to sell Sprout Pharmaceuticals, which initially won regulatory approval for the drug, back to its shareholders. The deal ends a lawsuit filed against the drug maker by former Sprout shareholders  – and Valeant is providing a $25 million loan.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Wrong advocacy group. Remember Hall and Oates “She’s a Maneater”. The NOW is a starchy postmenopsusal post womens libbers group that cares more about abortion rights than orgasms.

  • Hmmm – “and interactions with other medicines.” and if memory serves, that would include the ‘medicinal/ social effects of alcohol. This pill was indeed a solution that did seem to be somewhat … lacking.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.